Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb 1;85(Suppl 2):6–10. doi: 10.1054/bjoc.2001.1983

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?

A U Buzdar 1
PMCID: PMC2375168  PMID: 11900212

Abstract

Anastrozole (Arimidex™) is a third-generation aromatase inhibitor which has been shown to possess superior efficacy and tolerability over established endocrine agents in advanced breast cancer. Inhibition of aromatase prevents the conversion of androgen substrates to oestrogen, its sole source in postmenopausal women, thereby leading to regression of hormone-sensitive breast carcinomas. Clinical pharmacology data indicate that anastrozole is a potent aromatase inhibitor, providing near-maximal suppression of serum and intratumoural oestrogens to below detectable levels. Anastrozole may offer greater selectivity compared with other aromatase inhibitors, being without any intrinsic endocrine effects and with no apparent effect on the synthesis of adrenal steroids. It is well tolerated and has a convenient once-daily dosing regimen, ensuring maximum patient compliance. A major clinical programme has demonstrated that anastrozole is superior to the standard endocrine therapy, tamoxifen, for the first-line treatment of postmenopausal women with hormone-sensitive advanced breast cancer. Its superior efficacy in advanced disease, together with its improved tolerability and convenient dosage, make it a suitable agent to be assessed for the treatment of early breast cancer in postmenopausal women. This was investigated in the largest single adjuvant breast cancer study ever to be carried out, the ATAC (Arimidex, tamoxifen, alone or in combination) trial, which has now completed recruitment, with the first efficacy and safety data awaited. © 2001 Cancer Research Campaign

Keywords: anastrozole, aromatase inhibitor, tamoxifen, advanced breast cancer, adjuvant therapy, postmenopausal

Full Text

The Full Text of this article is available as a PDF (49.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajetta E., Zilembo N., Dowsett M., Guillevin L., Di Leo A., Celio L., Martinetti A., Marchianò A., Pozzi P., Stani S. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208–213. doi: 10.1016/s0959-8049(98)00392-x. [DOI] [PubMed] [Google Scholar]
  2. Bajetta E., Zilembo N., Noberasco C., Martinetti A., Mariani L., Ferrari L., Buzzoni R., Greco M., Bartoli C., Spagnoli I. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer. 1997 Apr;33(4):587–591. doi: 10.1016/s0959-8049(96)00494-7. [DOI] [PubMed] [Google Scholar]
  3. Baum M. Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocr Relat Cancer. 1999 Jun;6(2):231–234. doi: 10.1677/erc.0.0060231. [DOI] [PubMed] [Google Scholar]
  4. Bonneterre J., Thürlimann B., Robertson J. F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000 Nov 15;18(22):3748–3757. doi: 10.1200/JCO.2000.18.22.3748. [DOI] [PubMed] [Google Scholar]
  5. Buzdar A. U., Jonat W., Howell A., Jones S. E., Blomqvist C. P., Vogel C. L., Eiermann W., Wolter J. M., Steinberg M., Webster A. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998 Sep 15;83(6):1142–1152. [PubMed] [Google Scholar]
  6. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–1388. doi: 10.1093/jnci/90.18.1371. [DOI] [PubMed] [Google Scholar]
  7. Gale K. E., Andersen J. W., Tormey D. C., Mansour E. G., Davis T. E., Horton J., Wolter J. M., Smith T. J., Cummings F. J. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994 Jan 15;73(2):354–361. doi: 10.1002/1097-0142(19940115)73:2<354::aid-cncr2820730220>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Jones S., Vogel C., Arkhipov A., Fehrenbacher L., Eisenberg P., Cooper B., Honig S., Polli A., Whaley F., di Salle E. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol. 1999 Nov;17(11):3418–3425. doi: 10.1200/JCO.1999.17.11.3418. [DOI] [PubMed] [Google Scholar]
  9. Kaufmann M., Bajetta E., Dirix L. Y., Fein L. E., Jones S. E., Zilembo N., Dugardyn J. L., Nasurdi C., Mennel R. G., Cervek J. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000 Apr;18(7):1399–1411. doi: 10.1200/JCO.2000.18.7.1399. [DOI] [PubMed] [Google Scholar]
  10. Michaud L. B., Buzdar A. U. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf. 1999 Oct;21(4):297–309. doi: 10.2165/00002018-199921040-00005. [DOI] [PubMed] [Google Scholar]
  11. Nabholtz J. M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000 Nov 15;18(22):3758–3767. doi: 10.1200/JCO.2000.18.22.3758. [DOI] [PubMed] [Google Scholar]
  12. Plourde P. V., Dyroff M., Dowsett M., Demers L., Yates R., Webster A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):175–179. doi: 10.1016/0960-0760(95)00045-2. [DOI] [PubMed] [Google Scholar]
  13. Plourde P. V., Dyroff M., Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994;30(1):103–111. doi: 10.1007/BF00682745. [DOI] [PubMed] [Google Scholar]
  14. Smith I. E., Harris A. L., Morgan M., Gazet J. C., McKinna J. A. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982 Aug;42(8 Suppl):3430s–3433s. [PubMed] [Google Scholar]
  15. Yates R. A., Dowsett M., Fisher G. V., Selen A., Wyld P. J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer. 1996 Feb;73(4):543–548. doi: 10.1038/bjc.1996.94. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES